Testing Platelet Activation With a Shear-Dependent Platelet Function Test Versus Aggregation-Based Tests: Relevance for Monitoring Long-Term Glycoprotein IIb/IIIa Inhibition

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Circulation

• Publication date

  2001-03-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.103.11.1488PMID 11257073
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development.

  2000cited by this paper
• A revised model of platelet aggregation.

  2000cited by this paper
• Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists.

  2000cited by this paper
• Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor.

  2000cited by this paper
• Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy?

  1999cited by this paper
• Rapid platelet-function assay: an automated and quantitative cartridge-based method.

  1999cited by this paper
• Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.

  1999cited by this paper
• Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?

  1999cited by this paper
• Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism.

  1999cited by this paper
• Monitoring platelet GP IIb/IIIa antagonist therapy.

  1998cited by this paper
• Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.

  1998cited by this paper
• Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty.

  1995cited by this paper

• Effects of Exenatide on Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes

  2021cites this paper
• DDDT_A_312347 3027..3040

  2021cites this paper
• Effects of Exenatide on Blood Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes

  2021cites this paper
• Effects of Paclitaxel on the Ability of Aspirin and Clopidogrel to Inhibit Platelet Aggregation

  2016cites this paper
• Shear Stress‐Based Platelet Function Tests

  2014cites this paper
• The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.

  2014cites this paper
• Perioperative Management of Antithrombotic Medications in Vitreoretinal Surgery

  2014cites this paper
• Antiplatelet medications and evolving antithrombotic medication

  2013cites this paper
• Diagnostic Assessment of Platelet Function

  2013cites this paper
• In-vitro assessment of platelet function.

  2011cites this paper
• Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease.

  2010cites this paper
• DMSO inhibits human platelet activation through cyclooxygenase-1 inhibition. A novel agent for drug eluting stents?

  2010cites this paper
• Monitoring of Antithrombotic Therapies in Interventional Cardiology

  2010influential citation
• Point-of-Care Assessment of Antiplatelet Agents in the Perioperative Period: A Review

  2009cites this paper
• High-density fermentation and functional characterization of a recombinant echistatin mutant

  2009cites this paper
• A new oral antiplatelet agent with potent antithrombotic properties: Comparison of DZ-697b with clopidogrel in a randomised phase I study

  2009cites this paper
• Platelet function assessed by shear‐induced deposition of split triple‐dose apheresis concentrates treated with pathogen reduction technologies

  2009cites this paper
• New approaches in the measurement of coagulation

  2008cites this paper
• Effects of von Willebrand factor concentration and platelet collision on shear-induced platelet activation

  2008cites this paper
• Platelet reactivity and response to aspirin in subjects with the metabolic syndrome.

  2008cites this paper
• Platelet function testing in uraemic patients

  2008cites this paper
• Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence.

  2008cites this paper
• Testing agonist-induced platelet aggregation by the Impact-R [Cone and plate(let) analyzer (CPA)]

  2008cites this paper
• [Possibilities of platelet function assays].

  2007cites this paper
• Quality assessment of platelet rich plasma during anti-platelet therapy

  2007cites this paper
• Examination of platelet function in whole blood under dynamic flow conditions with the cone and plate(let) analyzer: effect of erythrocytosis and thrombocytosis.

  2007cites this paper
• Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin.

  2007cites this paper
• CHAPTER 29 – Impact Cone and Plate(let) Analyzer

  2007cites this paper
• Die Bedeutung der Thrombozytenaktivierung in der Pathogenese und Behandlung kardiologischer Erkrankungen

  2007cites this paper
• A novel anti‐ischemic nitric oxide donor (LA419) reduces thrombogenesis in healthy human subjects

  2007cites this paper
• Monitoring of the antiplatelet drugs effect in patients with coronary artery disease: what is the real clinical impact?

  2007cites this paper
• Current options in platelet function testing.

  2006cites this paper
• Impact – The Cone and Plate(let) Analyzer: Testing Platelet Function and Anti-Platelet Drug Response

  2006cites this paper
• Screening for Aspirin Responsiveness After Transient Ischemic Attack and Stroke: Comparison of 2 Point-of-Care Platelet Function Tests With Optical Aggregometry

  2005cites this paper
• Abciximab therapy is associated with increased platelet activation and decreased heparin dosage in patients with acute myocardial infarction

  2005cites this paper
• Dark chocolate improves endothelial and platelet function

  2005cites this paper
• Inhibiteurs du fonctionnement plaquettaire

  2005cites this paper
• Procoagulant activity of adherent platelets

  2005cites this paper
• Shear stress-dependent platelet function after LDL cholesterol apheresis.

  2004cites this paper
• Monitoring von Tienopyridinen und GPIIb/IIIa-Antagonisten

  2004cites this paper
• Integrilin Dose Optimization Using Cone Plate Analyzer – What Have We Learned Thus Far

  2004cites this paper
• Effects of the glycoprotein IIb/IIIa antagonist abciximab on thrombus formation and platelet function in cats with arterial injury.

  2003cites this paper
• Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban

  2003cites this paper
• Assessing platelet function during treatment with glycoprotein IIb/IIIa antagonists

  2003cites this paper
• Platelet Monitoring and Interaction of Glycoprotein IIb/IIIa Antagonists with Other Antiplatelet Agents

  2003cites this paper
• Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention

  2003cites this paper
• Coronary Atherosclerosis: Acute Coronary Syndromes

  2002cites this paper
• Glycoprotein IIb/IIIa antagonists - from bench to practice

  2002cites this paper
• Antithrombotic Effect of Tissue Factor Inhibition by Inactivated Factor VIIa: An Ex Vivo Human Study

  2002cites this paper
• Monitoring of platelet function in the setting of glycoprotein IIb/IIIa inhibitor therapy.

  2002cites this paper
• The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy.

  2002cites this paper
• Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention.

  2002cites this paper
• Comparative Analysis of Various Platelet Glycoprotein IIb/IIIa Antagonists on Shear-Induced Platelet Activation and Adhesion

  2002cites this paper
• Effects of Different Thrombolytic Treatment Regimen with Abciximab and Tirofiban on Platelet Aggregation and Platelet-Leukocyte Interactions: A Subgroup Analysis from the GUSTO V and FASTER Trials

  2002cites this paper
• ¿Se debe controlar el tratamiento con los bloqueadores de la glucoproteína IIb/IIIa en el intervencionismo coronario?

  2001cites this paper
• Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.

  2001cites this paper
• [Should treatment with glycoprotein IIa/IIIb receptor blocker be controlled in patients undergoing coronary intervention?].

  2001cites this paper